Filing Details

Accession Number:
0000899243-20-000659
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-06 21:15:50
Reporting Period:
2020-01-02
Accepted Time:
2020-01-06 21:15:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742485 Neil Kumar C/O Bridgebio Pharma, Inc.
421 Kipling Street
Palo Alto CA 94301
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-02 11,091 $32.55 2,994,281 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 19,793 $33.41 2,974,488 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 5,077 $34.19 2,969,411 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 100 $35.17 2,969,311 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-03 77,271 $32.14 2,892,040 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-03 6,668 $32.88 2,885,372 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,618,995 Direct
Common Stock 400,375 Indirect See footnote
Common Stock 927,686 Indirect See footnote
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019.
  2. Represents the weighted average sale price of the shares sold from $32.02 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7.
  3. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  4. Represents the weighted average sale price of the shares sold from $33.02 to $34.01 per share.
  5. Represents the weighted average sale price of the shares sold from $34.02 to $34.70 per share.
  6. Represents the weighted average sale price of the shares sold from $31.69 to $32.68 per share.
  7. Represents the weighted average sale price of the shares sold from $32.695 to $33.10 per share.
  8. The shares are held by Neil Kumar LLC. The Reporting Person is a member of Neil Kumar LLC and shares voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  9. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.